Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
Identifieur interne : 000082 ( Istex/Corpus ); précédent : 000081; suivant : 000083Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
Auteurs : Catherine J. Lees ; Vasso Apostolopoulos ; Bruce Acres ; Ian Ramshaw ; Alistair Ramsay ; Chin.-Swee Ong ; Ian F. C MckenzieSource :
- Vaccine [ 0264-410X ] ; 2000.
English descriptors
- KwdEn :
- Apostolopoulos, Control muc1, Ctlp, Ctlp frequencies, Ctlp frequency, Cytotoxic, Fusion protein, Human muc1, Immune, Immune responses, Immunisation, Immunised, Immunol, Inbred, Lees, Lysis, Mannan, Mice immunised, Mouse, Muc1, Muc1 ctlp frequency, Murine, Palpable tumors, Precursor, Recombinant, Single injection, Transgenic, Transgenic mice, Tumor cells, Tumor challenge, Tumor growth, Tumor protection, Tumour, Vaccine, Vaccinia, Vaccinia virus.
- Teeft :
- Apostolopoulos, Control muc1, Ctlp, Ctlp frequencies, Ctlp frequency, Cytotoxic, Fusion protein, Human muc1, Immune, Immune responses, Immunisation, Immunised, Immunol, Inbred, Lees, Lysis, Mannan, Mice immunised, Mouse, Muc1, Muc1 ctlp frequency, Murine, Palpable tumors, Precursor, Recombinant, Single injection, Transgenic, Transgenic mice, Tumor cells, Tumor challenge, Tumor growth, Tumor protection, Tumour, Vaccine, Vaccinia, Vaccinia virus.
Abstract
Abstract: Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8+ cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.
Url:
DOI: 10.1016/S0264-410X(00)00065-7
Links to Exploration step
ISTEX:0436D241201D03E24ACFA04DF57DB24A63713B39Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title><author><name sortKey="Lees, Catherine J" sort="Lees, Catherine J" uniqKey="Lees C" first="Catherine J" last="Lees">Catherine J. Lees</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Apostolopoulos, Vasso" sort="Apostolopoulos, Vasso" uniqKey="Apostolopoulos V" first="Vasso" last="Apostolopoulos">Vasso Apostolopoulos</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Acres, Bruce" sort="Acres, Bruce" uniqKey="Acres B" first="Bruce" last="Acres">Bruce Acres</name><affiliation><mods:affiliation>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</mods:affiliation></affiliation></author><author><name sortKey="Ramshaw, Ian" sort="Ramshaw, Ian" uniqKey="Ramshaw I" first="Ian" last="Ramshaw">Ian Ramshaw</name><affiliation><mods:affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</mods:affiliation></affiliation></author><author><name sortKey="Ramsay, Alistair" sort="Ramsay, Alistair" uniqKey="Ramsay A" first="Alistair" last="Ramsay">Alistair Ramsay</name><affiliation><mods:affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</mods:affiliation></affiliation></author><author><name sortKey="Ong, Chin Swee" sort="Ong, Chin Swee" uniqKey="Ong C" first="Chin.-Swee" last="Ong">Chin.-Swee Ong</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Mckenzie, Ian F C" sort="Mckenzie, Ian F C" uniqKey="Mckenzie I" first="Ian F. C" last="Mckenzie">Ian F. C Mckenzie</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: i.mckenzie@ari.unimelb.edu.au</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0436D241201D03E24ACFA04DF57DB24A63713B39</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S0264-410X(00)00065-7</idno><idno type="url">https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000082</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000082</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a">Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title><author><name sortKey="Lees, Catherine J" sort="Lees, Catherine J" uniqKey="Lees C" first="Catherine J" last="Lees">Catherine J. Lees</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Apostolopoulos, Vasso" sort="Apostolopoulos, Vasso" uniqKey="Apostolopoulos V" first="Vasso" last="Apostolopoulos">Vasso Apostolopoulos</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Acres, Bruce" sort="Acres, Bruce" uniqKey="Acres B" first="Bruce" last="Acres">Bruce Acres</name><affiliation><mods:affiliation>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</mods:affiliation></affiliation></author><author><name sortKey="Ramshaw, Ian" sort="Ramshaw, Ian" uniqKey="Ramshaw I" first="Ian" last="Ramshaw">Ian Ramshaw</name><affiliation><mods:affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</mods:affiliation></affiliation></author><author><name sortKey="Ramsay, Alistair" sort="Ramsay, Alistair" uniqKey="Ramsay A" first="Alistair" last="Ramsay">Alistair Ramsay</name><affiliation><mods:affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</mods:affiliation></affiliation></author><author><name sortKey="Ong, Chin Swee" sort="Ong, Chin Swee" uniqKey="Ong C" first="Chin.-Swee" last="Ong">Chin.-Swee Ong</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation></author><author><name sortKey="Mckenzie, Ian F C" sort="Mckenzie, Ian F C" uniqKey="Mckenzie I" first="Ian F. C" last="Mckenzie">Ian F. C Mckenzie</name><affiliation><mods:affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</mods:affiliation></affiliation><affiliation><mods:affiliation>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: i.mckenzie@ari.unimelb.edu.au</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="ISSN">0264-410X</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="158">158</biblScope><biblScope unit="page" to="162">162</biblScope></imprint><idno type="ISSN">0264-410X</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Apostolopoulos</term><term>Control muc1</term><term>Ctlp</term><term>Ctlp frequencies</term><term>Ctlp frequency</term><term>Cytotoxic</term><term>Fusion protein</term><term>Human muc1</term><term>Immune</term><term>Immune responses</term><term>Immunisation</term><term>Immunised</term><term>Immunol</term><term>Inbred</term><term>Lees</term><term>Lysis</term><term>Mannan</term><term>Mice immunised</term><term>Mouse</term><term>Muc1</term><term>Muc1 ctlp frequency</term><term>Murine</term><term>Palpable tumors</term><term>Precursor</term><term>Recombinant</term><term>Single injection</term><term>Transgenic</term><term>Transgenic mice</term><term>Tumor cells</term><term>Tumor challenge</term><term>Tumor growth</term><term>Tumor protection</term><term>Tumour</term><term>Vaccine</term><term>Vaccinia</term><term>Vaccinia virus</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Apostolopoulos</term><term>Control muc1</term><term>Ctlp</term><term>Ctlp frequencies</term><term>Ctlp frequency</term><term>Cytotoxic</term><term>Fusion protein</term><term>Human muc1</term><term>Immune</term><term>Immune responses</term><term>Immunisation</term><term>Immunised</term><term>Immunol</term><term>Inbred</term><term>Lees</term><term>Lysis</term><term>Mannan</term><term>Mice immunised</term><term>Mouse</term><term>Muc1</term><term>Muc1 ctlp frequency</term><term>Murine</term><term>Palpable tumors</term><term>Precursor</term><term>Recombinant</term><term>Single injection</term><term>Transgenic</term><term>Transgenic mice</term><term>Tumor cells</term><term>Tumor challenge</term><term>Tumor growth</term><term>Tumor protection</term><term>Tumour</term><term>Vaccine</term><term>Vaccinia</term><term>Vaccinia virus</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8+ cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.</div></front></TEI><istex><corpusName>elsevier</corpusName><keywords><teeft><json:string>muc1</json:string><json:string>ctlp</json:string><json:string>transgenic</json:string><json:string>immunised</json:string><json:string>transgenic mice</json:string><json:string>ctlp frequency</json:string><json:string>immunisation</json:string><json:string>murine</json:string><json:string>human muc1</json:string><json:string>immunol</json:string><json:string>mice immunised</json:string><json:string>immune</json:string><json:string>cytotoxic</json:string><json:string>recombinant</json:string><json:string>apostolopoulos</json:string><json:string>tumor protection</json:string><json:string>precursor</json:string><json:string>tumour</json:string><json:string>inbred</json:string><json:string>tumor cells</json:string><json:string>lysis</json:string><json:string>mouse</json:string><json:string>tumor challenge</json:string><json:string>mannan</json:string><json:string>vaccinia</json:string><json:string>tumor growth</json:string><json:string>single injection</json:string><json:string>vaccine</json:string><json:string>ctlp frequencies</json:string><json:string>palpable tumors</json:string><json:string>vaccinia virus</json:string><json:string>control muc1</json:string><json:string>fusion protein</json:string><json:string>immune responses</json:string><json:string>muc1 ctlp frequency</json:string><json:string>lees</json:string></teeft></keywords><author><json:item><name>Catherine J Lees</name><affiliations><json:string>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</json:string><json:string>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</json:string></affiliations></json:item><json:item><name>Vasso Apostolopoulos</name><affiliations><json:string>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</json:string></affiliations></json:item><json:item><name>Bruce Acres</name><affiliations><json:string>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</json:string></affiliations></json:item><json:item><name>Ian Ramshaw</name><affiliations><json:string>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</json:string></affiliations></json:item><json:item><name>Alistair Ramsay</name><affiliations><json:string>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</json:string></affiliations></json:item><json:item><name>Chin.-Swee Ong</name><affiliations><json:string>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</json:string></affiliations></json:item><json:item><name>Ian F.C McKenzie</name><affiliations><json:string>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</json:string><json:string>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</json:string><json:string>E-mail: i.mckenzie@ari.unimelb.edu.au</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Cytokines</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>Transgenic</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MUC1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>MUC1, human mucin 1</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>M-FP, mannan-MUC1 fusion protein</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>A2-MUC1, HLA-A*0201×MUC1 double transgenic mouse</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>CTLp, CTL precursor</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>VV, vaccinia virus</value></json:item></subject><arkIstex>ark:/67375/6H6-N4DSV516-N</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>Short communication</json:string></originalGenre><abstract>Abstract: Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8+ cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.</abstract><qualityIndicators><refBibsNative>true</refBibsNative><abstractWordCount>65</abstractWordCount><abstractCharCount>439</abstractCharCount><keywordCount>8</keywordCount><score>5.176</score><pdfWordCount>2396</pdfWordCount><pdfCharCount>14406</pdfCharCount><pdfVersion>1.2</pdfVersion><pdfPageCount>5</pdfPageCount><pdfPageSize>595 x 842 pts (A4)</pdfPageSize></qualityIndicators><title>Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title><pmid><json:string>10930667</json:string></pmid><pii><json:string>S0264-410X(00)00065-7</json:string></pii><genre><json:string>brief-communication</json:string></genre><host><title>Vaccine</title><language><json:string>unknown</json:string></language><publicationDate>2000</publicationDate><issn><json:string>0264-410X</json:string></issn><pii><json:string>S0264-410X(00)X0113-2</json:string></pii><volume>19</volume><issue>2–3</issue><pages><first>158</first><last>162</last></pages><genre><json:string>journal</json:string></genre></host><namedEntities><unitex><date><json:string>2000</json:string><json:string>420,000 to 1/240,000</json:string><json:string>55,000 to 1/19,000</json:string></date><geogName></geogName><orgName><json:string>Victoria University</json:string><json:string>Medical Research, Australian National University, Canberra, ACT, Australia</json:string><json:string>Division of Cell Biology</json:string><json:string>Department of Immunobiology, Transgene, SA</json:string><json:string>Elsevier Science Ltd.</json:string><json:string>Australia Victoria University of Technology, Centre for Bioprocessing and Food</json:string><json:string>Austin Research Institute</json:string><json:string>Research and Development Syndicate</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Catherine Lees</json:string><json:string>I.F.C. McKenzie</json:string><json:string>Curtin School</json:string><json:string>Alistair Ramsay</json:string></persName><placeName><json:string>Australia</json:string><json:string>Strasbourg</json:string><json:string>France</json:string></placeName><ref_url></ref_url><ref_bibl><json:string>[4]</json:string><json:string>[11]</json:string><json:string>[1]</json:string><json:string>[10]</json:string><json:string>[8,9]</json:string><json:string>C.J. Lees et al.</json:string><json:string>[2, 3]</json:string><json:string>[15]</json:string><json:string>[9]</json:string></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/6H6-N4DSV516-N</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - medicine, research & experimental</json:string><json:string>2 - immunology</json:string></wos><scienceMetrix><json:string>1 - health sciences</json:string><json:string>2 - biomedical research</json:string><json:string>3 - virology</json:string></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Infectious Diseases</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Public Health, Environmental and Occupational Health</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Veterinary</json:string><json:string>3 - General Veterinary</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - General Immunology and Microbiology</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Biochemistry, Genetics and Molecular Biology</json:string><json:string>3 - Molecular Medicine</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S0264-410X(00)00065-7</json:string></doi><id>0436D241201D03E24ACFA04DF57DB24A63713B39</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a">Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2000 Elsevier Science Ltd</p></availability><date>2000</date></publicationStmt><notesStmt><note type="content">Section title: Short Communication</note><note type="content">Fig. 1: Average CTLp frequencies from (A) BALB/c mice immunized I.P (×1 or ×3) with either 5 μg M-FP (□) or 5 μg M-FP+murine rIL-12 (■) (1 μg/mouse/day IP×5 days) (3 mice/group). The CTLp frequencies from mice injected with rIL-12 only were <1/106 (not shown); (B) MUC1 transgenic mice immunized I.P (either ×1 or ×3) with either 5 μg M-FP (□) or 5 μg M-FP+VVIL-12 (1×107 pfu/ml) (▨). The CTLp frequency for mice injected both ×1 and ×3 with VVIL-12 alone were <1/106 (not shown); and (C) A2-MUC1 transgenic mice immunized I.P (×3) with either 5 μg M-FP □ or 5 μg M-FP+VVIL-12 (1×107 pfu/ml) ▨. HLA-A2 restricted, MUC1 positive CTL precursors were determined using the MCF-7 target cell line and MUC1, H-2d CTL precursors were determined using the MUC1+ P815 target cell line. The CTLp frequencies from mice injected with VVIL-12 alone were <1/106 on both target cell lines (not shown).</note><note type="content">Fig. 2: MUC1 transgenic tumor challenge. (A) MUC1 transgenic mice (5–6/group) were injected with either pH 9.0 buffer (•), 5 μg M-FP (■), or 5 μg M-FP+VVIL-12 (▴) (1×107 pfu/ml) on days 0, 7 and 14 and challenged with 3.5×106 P815-MUC1 tumor cells on day 22 and tumor growth measured. (B) MUC1 transgenic mice (7–9/group) immunized intraperitoneally on days 0, 7 and 14 with either 5 μg M-FP, 5 μg M-FP+VV (1×107 pfu/ml), 5 μg M-FP+VVIL-12 (1×107 pfu/ml) or VVIL-12 (1×107 pfu/ml) and challenged on day 21 with 1×107 P815-MUC1 tumor cells. The number of mice with palpable tumors 30 days later are represented as a percentage of the total number of mice in each group with a tumor (± SE). Fisher’s Exact Test was used to determine the statistical significance of the data.</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a">Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title><author xml:id="author-0000"><persName><forename type="first">Catherine J</forename><surname>Lees</surname></persName><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><affiliation>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Vasso</forename><surname>Apostolopoulos</surname></persName><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Bruce</forename><surname>Acres</surname></persName><affiliation>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Ian</forename><surname>Ramshaw</surname></persName><affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Alistair</forename><surname>Ramsay</surname></persName><affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Chin.-Swee</forename><surname>Ong</surname></persName><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Ian F.C</forename><surname>McKenzie</surname></persName><email>i.mckenzie@ari.unimelb.edu.au</email><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><affiliation>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</affiliation></author><idno type="istex">0436D241201D03E24ACFA04DF57DB24A63713B39</idno><idno type="DOI">10.1016/S0264-410X(00)00065-7</idno><idno type="PII">S0264-410X(00)00065-7</idno></analytic><monogr><title level="j">Vaccine</title><title level="j" type="abbrev">JVAC</title><idno type="pISSN">0264-410X</idno><idno type="PII">S0264-410X(00)X0113-2</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">19</biblScope><biblScope unit="issue">2–3</biblScope><biblScope unit="page" from="158">158</biblScope><biblScope unit="page" to="162">162</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8+ cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.</p></abstract><textClass><keywords scheme="keyword"><list><head>Keywords</head><item><term>Cytokines</term></item><item><term>Transgenic</term></item><item><term>MUC1</term></item></list></keywords></textClass><textClass><keywords scheme="keyword"><list><head>Abbreviations</head><item><term>MUC1, human mucin 1</term></item><item><term>M-FP, mannan-MUC1 fusion protein</term></item><item><term>A2-MUC1, HLA-A*0201×MUC1 double transgenic mouse</term></item><item><term>CTLp, CTL precursor</term></item><item><term>VV, vaccinia virus</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="1999-09-17">Modified</change><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier, elements deleted: ce:floats; body; tail"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 4.5.2//EN//XML" URI="art452.dtd" name="istex:docType"><istex:entity SYSTEM="gr1" NDATA="IMAGE" name="gr1"></istex:entity><istex:entity SYSTEM="gr2" NDATA="IMAGE" name="gr2"></istex:entity></istex:docType><istex:document><converted-article version="4.5.2" docsubtype="sco"><item-info><jid>JVAC</jid><aid>2070</aid><ce:pii>S0264-410X(00)00065-7</ce:pii><ce:doi>10.1016/S0264-410X(00)00065-7</ce:doi><ce:copyright type="full-transfer" year="2000">Elsevier Science Ltd</ce:copyright></item-info><head><ce:dochead><ce:textfn>Short Communication</ce:textfn></ce:dochead><ce:title>Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</ce:title><ce:author-group><ce:author><ce:initials>C.J.</ce:initials><ce:given-name>Catherine J</ce:given-name><ce:surname>Lees</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="AFF2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>V.</ce:initials><ce:given-name>Vasso</ce:given-name><ce:surname>Apostolopoulos</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>B.</ce:initials><ce:given-name>Bruce</ce:given-name><ce:surname>Acres</ce:surname><ce:cross-ref refid="AFF3"><ce:sup>c</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>I.</ce:initials><ce:given-name>Ian</ce:given-name><ce:surname>Ramshaw</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>A.</ce:initials><ce:given-name>Alistair</ce:given-name><ce:surname>Ramsay</ce:surname><ce:cross-ref refid="AFF4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>C-S.</ce:initials><ce:given-name>Chin.-Swee</ce:given-name><ce:surname>Ong</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref></ce:author><ce:author><ce:initials>I.F.C.</ce:initials><ce:given-name>Ian F.C</ce:given-name><ce:surname>McKenzie</ce:surname><ce:cross-ref refid="AFF1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="CORR1">*</ce:cross-ref><ce:e-address>i.mckenzie@ari.unimelb.edu.au</ce:e-address></ce:author><ce:affiliation id="AFF1"><ce:label>a</ce:label><ce:textfn>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</ce:textfn></ce:affiliation><ce:affiliation id="AFF2"><ce:label>b</ce:label><ce:textfn>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</ce:textfn></ce:affiliation><ce:affiliation id="AFF3"><ce:label>c</ce:label><ce:textfn>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</ce:textfn></ce:affiliation><ce:affiliation id="AFF4"><ce:label>d</ce:label><ce:textfn>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</ce:textfn></ce:affiliation><ce:correspondence id="CORR1"><ce:label>*</ce:label><ce:text>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</ce:text></ce:correspondence></ce:author-group><ce:date-received day="5" month="8" year="1999"></ce:date-received><ce:date-revised day="17" month="9" year="1999"></ce:date-revised><ce:date-accepted day="22" month="12" year="1999"></ce:date-accepted><ce:abstract><ce:section-title>Abstract</ce:section-title><ce:abstract-sec><ce:simple-para>Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8<ce:sup>+</ce:sup> cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.</ce:simple-para></ce:abstract-sec></ce:abstract><ce:keywords class="keyword"><ce:section-title>Keywords</ce:section-title><ce:keyword><ce:text>Cytokines</ce:text></ce:keyword><ce:keyword><ce:text>Transgenic</ce:text></ce:keyword><ce:keyword><ce:text>MUC1</ce:text></ce:keyword></ce:keywords><ce:keywords class="abr"><ce:section-title>Abbreviations</ce:section-title><ce:keyword><ce:text>MUC1, human mucin 1</ce:text></ce:keyword><ce:keyword><ce:text>M-FP, mannan-MUC1 fusion protein</ce:text></ce:keyword><ce:keyword><ce:text>A2-MUC1, HLA-A*0201×MUC1 double transgenic mouse</ce:text></ce:keyword><ce:keyword><ce:text>CTLp, CTL precursor</ce:text></ce:keyword><ce:keyword><ce:text>VV, vaccinia virus</ce:text></ce:keyword></ce:keywords></head></converted-article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo><title>Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title></titleInfo><titleInfo type="alternative" contentType="CDATA"><title>Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice</title></titleInfo><name type="personal"><namePart type="given">Catherine J</namePart><namePart type="family">Lees</namePart><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><affiliation>Victoria University of Technology, Centre for Bioprocessing and Food Technology, Werribee 3030, Victoria, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Vasso</namePart><namePart type="family">Apostolopoulos</namePart><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Bruce</namePart><namePart type="family">Acres</namePart><affiliation>Department of Immunobiology, Transgene, SA, 11 rue de Molsheim, 67082 Strasbourg, France</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ian</namePart><namePart type="family">Ramshaw</namePart><affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Alistair</namePart><namePart type="family">Ramsay</namePart><affiliation>Division of Cell Biology, John Curtin School of Medical Research, Australian National University, Canberra, ACT, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Chin.-Swee</namePart><namePart type="family">Ong</namePart><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Ian F.C</namePart><namePart type="family">McKenzie</namePart><affiliation>The Austin Research Institute, Studley Rd, Heidelberg 3084, Victoria, Australia</affiliation><affiliation>Corresponding author. Tel.: +61-3-92870-666; fax: +61-3-92870-600</affiliation><affiliation>E-mail: i.mckenzie@ari.unimelb.edu.au</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="brief-communication" displayLabel="Short communication" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-S9SX2MFS-0">brief-communication</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><dateModified encoding="w3cdtf">1999-09-17</dateModified><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><abstract lang="en">Abstract: Mice immunised with oxidised mannan-MUC1 fusion protein (M-FP) develop MHC restricted CD8+ cytotoxic T cells. We now demonstrate that in MUC1/HLA-A2 transgenic mice, IL-12 gives enhanced CTL, CTLp and tumor protection. CTLp in MUC1 transgenic mice with M-FP were 1/55,000, and with IL-12, this increased to 1/19,000, with improved tumor protection. Thus, IL-12 is important for effective CTL responses to MUC1 in transgenic mice.</abstract><note type="content">Section title: Short Communication</note><note type="content">Fig. 1: Average CTLp frequencies from (A) BALB/c mice immunized I.P (×1 or ×3) with either 5 μg M-FP (□) or 5 μg M-FP+murine rIL-12 (■) (1 μg/mouse/day IP×5 days) (3 mice/group). The CTLp frequencies from mice injected with rIL-12 only were <1/106 (not shown); (B) MUC1 transgenic mice immunized I.P (either ×1 or ×3) with either 5 μg M-FP (□) or 5 μg M-FP+VVIL-12 (1×107 pfu/ml) (▨). The CTLp frequency for mice injected both ×1 and ×3 with VVIL-12 alone were <1/106 (not shown); and (C) A2-MUC1 transgenic mice immunized I.P (×3) with either 5 μg M-FP □ or 5 μg M-FP+VVIL-12 (1×107 pfu/ml) ▨. HLA-A2 restricted, MUC1 positive CTL precursors were determined using the MCF-7 target cell line and MUC1, H-2d CTL precursors were determined using the MUC1+ P815 target cell line. The CTLp frequencies from mice injected with VVIL-12 alone were <1/106 on both target cell lines (not shown).</note><note type="content">Fig. 2: MUC1 transgenic tumor challenge. (A) MUC1 transgenic mice (5–6/group) were injected with either pH 9.0 buffer (•), 5 μg M-FP (■), or 5 μg M-FP+VVIL-12 (▴) (1×107 pfu/ml) on days 0, 7 and 14 and challenged with 3.5×106 P815-MUC1 tumor cells on day 22 and tumor growth measured. (B) MUC1 transgenic mice (7–9/group) immunized intraperitoneally on days 0, 7 and 14 with either 5 μg M-FP, 5 μg M-FP+VV (1×107 pfu/ml), 5 μg M-FP+VVIL-12 (1×107 pfu/ml) or VVIL-12 (1×107 pfu/ml) and challenged on day 21 with 1×107 P815-MUC1 tumor cells. The number of mice with palpable tumors 30 days later are represented as a percentage of the total number of mice in each group with a tumor (± SE). Fisher’s Exact Test was used to determine the statistical significance of the data.</note><subject><genre>Keywords</genre><topic>Cytokines</topic><topic>Transgenic</topic><topic>MUC1</topic></subject><subject><genre>Abbreviations</genre><topic>MUC1, human mucin 1</topic><topic>M-FP, mannan-MUC1 fusion protein</topic><topic>A2-MUC1, HLA-A*0201×MUC1 double transgenic mouse</topic><topic>CTLp, CTL precursor</topic><topic>VV, vaccinia virus</topic></subject><relatedItem type="host"><titleInfo><title>Vaccine</title></titleInfo><titleInfo type="abbreviated"><title>JVAC</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">20000915</dateIssued></originInfo><identifier type="ISSN">0264-410X</identifier><identifier type="PII">S0264-410X(00)X0113-2</identifier><part><date>20000915</date><detail type="volume"><number>19</number><caption>vol.</caption></detail><detail type="issue"><number>2–3</number><caption>no.</caption></detail><extent unit="issue-pages"><start>155</start><end>384</end></extent><extent unit="pages"><start>158</start><end>162</end></extent></part></relatedItem><identifier type="istex">0436D241201D03E24ACFA04DF57DB24A63713B39</identifier><identifier type="ark">ark:/67375/6H6-N4DSV516-N</identifier><identifier type="DOI">10.1016/S0264-410X(00)00065-7</identifier><identifier type="PII">S0264-410X(00)00065-7</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Ltd</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-HKKZVM7B-M">elsevier</recordContentSource><recordOrigin>Elsevier Science Ltd, ©2000</recordOrigin></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/document/0436D241201D03E24ACFA04DF57DB24A63713B39/metadata/json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000082 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 000082 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:0436D241201D03E24ACFA04DF57DB24A63713B39
|texte= Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice
}}
| This area was generated with Dilib version V0.6.33. |  |